Exelixis in-licenses Aurigene’s novel CDK7 inhibitor and files investigational new drug application for phase 1 clinical trial in advanced solid tumors
– Phase 1 clinical trial expected to begin in Q1 2021 – Under the terms of the companies’ agreement, Exelixis will make an option exercise payment of $12 million to
Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor – Detailed characterization of an oral
PRESS RELEASE Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis Bangalore, February 17, 2020 — Aurigene, a development stage
PRESS RELEASE Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 – Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in
